Macular Hole Closure with Medical Treatment

Jared T. Sokol; Sidney A. Schechet; Rahul Komati; Dean Eliott; Demetrios G. Vavvas; Richard I. Kaplan; Shaun T. Ittiara; Asim V. Farooq; Veeral S. Sheth; Mathew W. MacCumber; Rhona Ke; Ronald C. Gentile; Dimitra Skondra

doi:10.1016/j.oret.2020.11.018

Macular Hole Closure with Medical Treatment

Jared T. Sokol, Sidney A. Schechet, Rahul Komati, Dean Eliott, Demetrios G. Vavvas, Richard I. Kaplan, Shaun T. Ittiara, Asim V. Farooq, Veeral S. Sheth, Mathew W. MacCumber, Rhona Ke, Ronald C. Gentile, Dimitra Skondra

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Original language	English
Pages (from-to)	711-713
Number of pages	3
Journal	Ophthalmology Retina
Volume	5
Issue number	7
DOIs	https://doi.org/10.1016/j.oret.2020.11.018
State	Published - Jul 2021
Externally published	Yes

Keywords

Macular hole
Macular surgery
Vitreoretinal surgery

Access to Document

10.1016/j.oret.2020.11.018

Cite this

@article{461e22eabd44477eb172901382f48929,

title = "Macular Hole Closure with Medical Treatment",

keywords = "Macular hole, Macular surgery, Vitreoretinal surgery",

author = "Sokol, {Jared T.} and Schechet, {Sidney A.} and Rahul Komati and Dean Eliott and Vavvas, {Demetrios G.} and Kaplan, {Richard I.} and Ittiara, {Shaun T.} and Farooq, {Asim V.} and Sheth, {Veeral S.} and MacCumber, {Mathew W.} and Rhona Ke and Gentile, {Ronald C.} and Dimitra Skondra",

note = "Funding Information: Disclosure(s): All authors have completed and submitted the ICMJE disclosures form. The author(s) have made the following disclosure(s): D.S.: Consultant - Allergan, Alimera Sciences, Biogen D.E.: Consultant - Alcon, Alimera Sciences, Allergan, Dutch Ophthalmic, Genentech, Regenxbio, Aldeyra Therapeutics; Financial support - NeurotechS.I.: Financial support - Allergan, Alimera SciencesR.C.G.: Financial support - Alcon Laboratories, Inc., Acucela, Genentech, GlaxoSmithKline, Notal Vision, Inc., Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc.Supported by the Juvenile Diabetes Research Foundation, New York, New York (R.C.G.); the National Eye Institute, National Institutes of Health, Bethesda, Maryland (R.C.G.); New York Eye and Ear Infirmary of Mount Sinai, New York, New York (R.C.G.); the University of Wisconsin, Madison, Wisconsin (R.C.G.); Diabetic Retinopathy Clinical Research Network, Tampa, Florida (R.C.G.). D.S.: Consultant - Allergan, Biogen, Alimera Sciences. Obtained funding: N/A",

year = "2021",

month = jul,

doi = "10.1016/j.oret.2020.11.018",

language = "English",

volume = "5",

pages = "711--713",

journal = "Ophthalmology Retina",

issn = "2468-6530",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Macular Hole Closure with Medical Treatment

AU - Sokol, Jared T.

AU - Schechet, Sidney A.

AU - Komati, Rahul

AU - Eliott, Dean

AU - Vavvas, Demetrios G.

AU - Kaplan, Richard I.

AU - Ittiara, Shaun T.

AU - Farooq, Asim V.

AU - Sheth, Veeral S.

AU - MacCumber, Mathew W.

AU - Ke, Rhona

AU - Gentile, Ronald C.

AU - Skondra, Dimitra

N1 - Funding Information: Disclosure(s): All authors have completed and submitted the ICMJE disclosures form. The author(s) have made the following disclosure(s): D.S.: Consultant - Allergan, Alimera Sciences, Biogen D.E.: Consultant - Alcon, Alimera Sciences, Allergan, Dutch Ophthalmic, Genentech, Regenxbio, Aldeyra Therapeutics; Financial support - NeurotechS.I.: Financial support - Allergan, Alimera SciencesR.C.G.: Financial support - Alcon Laboratories, Inc., Acucela, Genentech, GlaxoSmithKline, Notal Vision, Inc., Quark Pharmaceuticals, Regeneron Pharmaceuticals, Inc.Supported by the Juvenile Diabetes Research Foundation, New York, New York (R.C.G.); the National Eye Institute, National Institutes of Health, Bethesda, Maryland (R.C.G.); New York Eye and Ear Infirmary of Mount Sinai, New York, New York (R.C.G.); the University of Wisconsin, Madison, Wisconsin (R.C.G.); Diabetic Retinopathy Clinical Research Network, Tampa, Florida (R.C.G.). D.S.: Consultant - Allergan, Biogen, Alimera Sciences. Obtained funding: N/A

PY - 2021/7

Y1 - 2021/7

KW - Macular hole

KW - Macular surgery

KW - Vitreoretinal surgery

UR - http://www.scopus.com/inward/record.url?scp=85100379644&partnerID=8YFLogxK

U2 - 10.1016/j.oret.2020.11.018

DO - 10.1016/j.oret.2020.11.018

M3 - Article

C2 - 33338669

AN - SCOPUS:85100379644

VL - 5

SP - 711

EP - 713

JO - Ophthalmology Retina

JF - Ophthalmology Retina

SN - 2468-6530

IS - 7

ER -